Contrarily, hypoglycemic agents such as GLP-1 agonists, DPP-4 inhibitors, thiazolidinediones and biguanides seem to reduce incidence of autoinflammatory and autoimmune disorders including PSO and alleviate the disease severity [41,153,154,155]. Here, DPP4 is linked to autoimmune disease.